Clinical trial
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute…
NCT00180115 · Technische Universität Dresden, Other · Completed
Key facts
| NCT number | NCT00180115 |
|---|---|
| Title | AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients |
| Official title | AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. |
| Lead sponsor | Technische Universität Dresden, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Leukemia, Nonlymphoblastic, Acute |
| Intervention type | Drug |
| Interventions | Cytarabine Dosage |
| Enrollment | 400 |
| Start date | Feb 1, 1996 |
| Completion | Nov 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 17, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: